Novel Treatment Combination Improves Progression-Free Survival in Most Common Form of Metastatic Breast Cancer - Poll - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Novel Treatment Combination Improves Progression-Free Survival in Most Common Form of Metastatic Breast Cancer

Patients with estrogen-receptor-positive (ER+) HER-2-negative advanced breast cancer experienced significantly improved progression-free survival (PFS) when treated with an oral combination regimen that included giredestrant, a novel, next-generation selective ER degrader and full antagonist (SERD), compared to a standard combination approach.

  • By

  • October 1, 2026

  • 4 min

Share

Original Source(s)

Novel Treatment Combination Improves Progression-Free Survival in Most Common Form of Metastatic Breast Cancer

  • by

  • October 1, 2026

Related Content

When Historical Housing Policy Shapes Modern Breast Cancer Prevention

Medically Assisted Reproduction and Hormone-Related Cancers

2026 ASCO Breast Cancer Highlights: Food Access, Poverty, and MBC

Harold Burstein, MD, PhD, and Rachel Freedman, MD, MPH discuss the results of a new study looking at the impact of food access and poverty on patients with metastatic breast cancer. They also discuss the new Dana-Farber food pantry and patient navigators who help coordinate care.

  • October 15, 2026

  • 1 min